We put forward the hypothesis that higher activation levels of the TLR9/TGF-β1/PDGF-B pathway in SLE patients are associated with increased levels of TLR9, TGF-β1, and PDGF-B in the blood of SLE patients. This evidence concerns the gene TLR9 and systemic lupus erythematosus.